What is 35Pharma?
35Pharma operates at the intersection of advanced protein engineering and clinical medicine. The company is dedicated to the design and development of innovative therapeutics that target the TGF-beta superfamily, with a specialized focus on Activin and GDF biology. Their core competency lies in the creation of multi-specific ligand traps, which are engineered for high selectivity and potency. This technological platform is designed to address complex, high-burden conditions including pulmonary hypertension, heart failure, and obesity. By leveraging a team with deep expertise in biologics, 35Pharma is effectively bridging the gap between laboratory-scale innovation and large-scale clinical application, aiming to deliver transformative patient outcomes in areas of significant unmet medical need.
How much funding has 35Pharma raised?
35Pharma has raised a total of $53M across 1 funding round:
Series C
$53M
Series C (2024): $53M with participation from Vivo Capital, Frazier Life Sciences Management, and Deep Track Capital
Key Investors in 35Pharma
Vivo Capital
Vivo Capital is a global healthcare investment firm founded in 1996 that manages private and public equity, as well as venture capital, to support innovative medical companies.
Frazier Life Sciences Management
Frazier Life Sciences is a prominent biotech investment firm that leverages both venture and public strategies to build companies focused on developing novel therapeutics.
Deep Track Capital
Deep Track Capital is a Greenwich-based investment firm that specializes exclusively in the life sciences industry, providing targeted support to biotechnology stakeholders.
What's next for 35Pharma?
With the recent influx of capital, 35Pharma is well-positioned to transition into a more mature phase of its corporate lifecycle. The strategic roadmap focuses on the rapid advancement of HS235, utilizing the newly acquired resources to streamline clinical trial operations and expand its internal research capabilities. Investors are likely looking for the company to hit key clinical milestones that validate the efficacy of its ligand trap platform. As the firm scales, the focus will shift toward optimizing manufacturing processes and preparing for potential regulatory submissions. This major enterprise-level funding provides the stability required to navigate the high-risk, high-reward environment of biotech development, ensuring that 35Pharma remains at the forefront of therapeutic innovation in the coming years.
See full 35Pharma company page
